 |
|
|
| |
9th European AIDS Conference (EACS)
Warsaw, Poland, Oct 25-29, 2003 |
| |
| |
- CC chemokine receptor 5 Delta32 polymorphism in two independent cohorts of hepatitis C virus infected patients without hemophilia - (12/16/03)
- Pegasys plus Ribavirin for HCV Treatment in HIV/HCV Coinfection in spain: PRESCO Study - (12/16/03)
- THE TREATMENT OF ACUTE HEPATITIS C INFECTION IN HIV-COINFECTED PATIENTS - A RETROSPECTIVE ANALYSIS OF 8 CASES IN A MULTICENTER SETTING - (12/16/03)
- The Impact of Depression on HAART Effectiveness - (12/16/03)
- ALT & AST Changes Over 48 weeks in HIV+ Therapy-Naïve Adults with Hepatitis B and/ot C Co-Infection Treated with Fosamprenavir QD or Nelfinavir: SOLO Study - (12/16/03)
- LIVER TOXICITY OF LOPINAVIR/RITONAVIR-CONTAINING REGIMENS IN HIV-INFECTED PATIENTS WITH OR WITHOUT HEPATITIS C VIRUS (HCV) CO-INFECTION - (12/16/03)
- Atazanavir Maintained Patient Utility and Improved Quality of Life, Comparing Favorably to LPV/RTV: 24-Week Data from BMS 043 - (11/31/03)
- Virologic Determinants of 24-Week Efficacy of Atazanavir With or Without Ritonavir in Patients with Prior Failure of a Protease Inhibitor - (11/31/03)
- Prevalence of HIV and Hepatitis B and C Among Drug Addicts in the Holy City of Amritsar, India - (11/31/03)
- FUZEON: EFFICACY OF ENFUVIRTIDE (Fuzeon) IN SUBGROUPS OF PATIENTS THROUGH 48 WEEKS OF THERAPY IN THE TORO TRIALS - (11/31/03)
- FUZEON: PATIENT ACCEPTANCE WITH SELF-INJECTION OF ENFUVIRTIDE (Fuzeon) FOR HIV OVER 48 WEEKS OF TREATMENT - (11/31/03)
- FUZEON: IMPACT OF ENFUVIRTIDE (Fuzeon) ON HEALTH-RELATED QUALITY OF LIFE AT 48 WEEKS - (11/31/03)
- Atazanavir Maintained Patient Utility and Improved Quality of Life, Comparing Favorably to LPV/RTV: 24-Week Data from BMS 043 - (11/31/03)
- 2 Year Long Term Safety Profile of Tenofovir DF (TDF) in Treatment-Experienced Patients from Randomized, Double-Blind, Placebo-Controlled Clinical Trials - (11/31/03)
- Once Daily Saquinavir/r: pharmacokinetcs (drug levels) and bioequivalence of new 500 mg Invirase tablet - (11/24/03)
- EPIDEMIOLOGY OF IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN AN ETHNICALLY DIVERSE HIV INFECTED COHORT - (11/21/03)
- MATERNAL TOLERABILITY OF ANTIRETROVIRAL THERAPY IN PREVENTING VERTICAL TRANSMISSION OF HIV-1 - (11/21/03)
- DRAMATIC REDUCTION, BUT NO ELIMINATION, OF PERINATAL HIV TRANSMISSION - (11/21/03)
- Atazanavir is Associated with Better Patient Adherence: Long-Term Follow-Up Data from BMS 041 and 044 Studies - (11/21/03)
- Assisted Medical Procreation for HIV+ Couples & Pregnancy - (11/19/03)
- Increase in Mitochondrial DNA in PBMCs Following switch from d4T to Tenofovir - (11/19/03)
- Atazanavir Once Daily Protease Inhibitor Adherence Evaluated - (11/19/03)
- Lopinavir/r (Kaletra) As Sole Therapy for HIV - (11/19/03)
- Assisted Medical Procreation for HIV+ and HCV+ Couples & Pregnancy - (11/19/03)
- Increase in Mitochondrial DNA in PBMCs Following switch from d4T to Tenofovir - (11/19/03)
- Atazanavir Once Daily Protease Inhibitor Adherence Evaluated - (11/19/03)
- Lopinavir/r (Kaletra) As Sole Therapy for HIV - (11/19/03)
- Trizivir in Treatment-Naives: can it still be considered as a first line treatment option? - (11/18/03)
- Kaletra resistance: hard to find in first line and second line use - Graeme Moyle, MD, Chelsea & Westminster Hospital, London, UK - (11/18/03)
- Switching from PI to Trizivir or Nevirapine Due to Lipid Abnormalities - (11/17/03)
- Hypophosphataemia in Patients Taking Tenofovir - (11/13/03)
- 4 Drug HAART Regimen vs 3 Drug Regimen: Combivir vs Trizivir plus SQV/r (1000/100 mg bid) - (11/10/03)
- IL-2 effectively increases CD4 count in persons with low CD4 nadir - Graeme Moyle, MD, Chelsea & Westminster Hospital, London, UK - (11/10/03)
- Heart Disease & Hepatotoxicity Among Leading Causes for Hospitalizations - (11/06/03)
- Tipranavir Report from 2003 European AIDS Conference - (11/06/03)
- Once Daily Kaletra; 24 week study results - (11/05/03)
- 5-Year Results of Lopinavir/ritonavir (LPV/r)-Based Therapy in Antiretroviral-Naïve HIV-Infected Patients - (11/05/03)
- Is Kaletra a once daily protease inhibitor? - Graeme Moyle, MD, Chelsea & Westminster Hospital, London, UK - (11/04/03)
- Resistance: Atazanavir, Atazanavir/rtv, and Kaletra--studies 043, 045 - Graeme Moyle, MD, Chelsea & Westminster Hospital, London, UK - (11/04/03)
- HCV Sexual Transmission --MSM & Heterosexual - (11/04/03)
- Kaletra Drug levels in HCV/HIV Coinfection - (11/04/03)
|
|
| |
|
|
|
|
|
|
